The Democratic Party needs a new generation of uncompromised politicians. This country needs people who will fight to end the genocide in Gaza, tax the billionaires, and hold the Epstein Class accountable.

I’m happy to share that I’m starting a new position as Advisor at Elderberry Ventures! Once you understand the story behind the fund, you’ll understand why. Catherine Kiani, J.D.grew up with a front-row seat to one of MedTech’s most remarkable company-building stories. @elderberry She watched her father, @JoeKiani , build Masimo from a garage startup into a global MedTech institution, one that generated more than $2B in 2025 revenue, beat Apple in court, and was ultimately acquired by Danaher for $9.9B. But Catherine didn’t only see the outcome. She saw what it took to get there: breakthrough technology, regulatory persistence, strong intellectual property, clinical trust, and the conviction to keep building before the market recognized the opportunity. After developing her own career across healthcare policy, law, venture investing, and M&A, Catherine is bringing those experiences together through Elderberry. The thesis is simple: most funds wait for consensus. Elderberry is built to invest before it. Today, generalist venture capital is moving upstream while promising seed-stage MedTech companies approach critical clinical and regulatory milestones. Many have validated technology, a real unmet need, and a credible path forward but the market has not yet recognized or priced their potential. That creates what we call the "Clinical Inflection Gap."" Elderberry invests within that gap across medtech, healthTech, and connected devices and a small percentage of the fund is for non healthcare moonshot investments. Catherine gets access to some amazing, world changing ideas so why not allocate some small amount on these bets? Having Joe’s four decades of experience and pattern recognition behind that network is the icing on top. I’ll support the fund across sourcing, diligence, market strategy, and company building, helping identify meaningful technologies and supporting founders as they cross the traction gap, craft their category, and engineer the market around it. I’m honored to join Catherine, Joe, and an incredible group of advisors backing the next generation of patient care before the opportunity becomes obvious. If you’re building an early-stage MedTech, HealthTech, or connected